NASDAQ:QTTB Q32 Bio (QTTB) Stock Price, News & Analysis $1.66 -0.11 (-6.21%) Closing price 05/21/2025 04:00 PM EasternExtended Trading$1.66 +0.00 (+0.24%) As of 05/21/2025 04:04 PM Eastern Extended trading is trading that happens on electronic markets outside of regular trading hours. This is a fair market value extended hours price provided by Polygon.io. Learn more. Add Compare Share Share Stock Analysis Stock AnalysisAnalyst ForecastsChartCompetitorsEarningsHeadlinesInsider TradesOwnershipSEC FilingsShort InterestTrendsBuy This Stock About Q32 Bio Stock (NASDAQ:QTTB) 30 days 90 days 365 days Advanced Chart View Price History Chart DataSkip Price History Chart Get Q32 Bio alerts:Sign Up Key Stats Today's Range$1.62▼$1.7550-Day Range$1.45▼$2.1952-Week Range$1.38▼$53.79Volume169,012 shsAverage Volume195,751 shsMarket Capitalization$20.25 millionP/E RatioN/ADividend YieldN/APrice Target$24.71Consensus RatingHold Company OverviewQ32 Bio Inc., a clinical-stage biotechnology company, develops biologic therapeutics to restore healthy immune balance in patients with autoimmune and inflammatory diseases driven by pathological immune dysfunction in the United States. Its lead product candidate is ADX-097, a humanized anti-C3d monoclonal antibody fusion protein to restore complement regulation, which has completed Phase I clinical trial for the treatment of renal and other complement-mediated diseases of high unmet need, including lupus nephritis, immunoglobulin A nephropathy, complement component 3 glomerulopathy, and anti-neutrophil cytoplasmic antibody-associated vasculitis. The company is also developing Bempikibart (ADX-914), a fully human antiinterleukin-7 receptor alpha antagonist monoclonal antibody designed to re-regulate adaptive immune function by blocking signaling mediated by interleukin-7 and thymic stromal lymphopoietin that is Phase II clinical trial for the treatment of atopic dermatitis and alopecia areata. Q32 Bio Inc. was formerly known as AdMIRx Inc. and changed its name to Q32 Bio Inc. in April 2020. The company was founded in 2017 and is based in Waltham, Massachusetts.Read More… Q32 Bio Stock Analysis - MarketRank™See Top-Rated MarketRank™ Stocks42nd Percentile Overall ScoreQTTB MarketRank™: Q32 Bio scored higher than 42% of companies evaluated by MarketBeat, and ranked 616th out of 915 stocks in the medical sector. Scores are calculated by averaging available category scores, with extra weight given to analysis and valuation. Analyst's Opinion3.1 / 5Analyst RatingHold Consensus RatingQ32 Bio has received a consensus rating of Hold. The company's average rating score is 2.25, and is based on 2 buy ratings, 6 hold ratings, and no sell ratings.Amount of Analyst CoverageQ32 Bio has only been the subject of 1 research reports in the past 90 days.Read more about Q32 Bio's stock forecast and price target. Earnings and Valuation1.3 / 5Proj. Earnings GrowthGrowing Earnings GrowthEarnings for Q32 Bio are expected to grow in the coming year, from ($12.32) to ($3.84) per share.Price to Earnings Ratio vs. the MarketThe P/E ratio of Q32 Bio is -0.12, which means that its earnings are negative and its P/E ratio cannot be compared to companies with positive earnings.Price to Earnings Ratio vs. SectorThe P/E ratio of Q32 Bio is -0.12, which means that its earnings are negative and its P/E ratio cannot be compared to companies with positive earnings.Price to Book Value per Share RatioQ32 Bio has a P/B Ratio of 0.07. P/B Ratios below 1 indicate that a company could be undervalued with respect to its assets and liabilities. Short Interest4.0 / 5Short Interest LevelHealthy Percentage of Shares Shorted12.54% of the float of Q32 Bio has been sold short.Short Interest Ratio / Days to CoverQ32 Bio has a short interest ratio ("days to cover") of 2.6, which is generally considered an acceptable ratio of short interest to trading volume.Change versus previous monthShort interest in Q32 Bio has recently decreased by 21.19%, indicating that investor sentiment is improving significantly. Dividend0.0 / 5Dividend StrengthN/A Dividend YieldQ32 Bio does not currently pay a dividend.Dividend GrowthQ32 Bio does not have a long track record of dividend growth. Sustainability and ESGN/AEnvironmental ScoreN/A Percentage of Shares Shorted12.54% of the float of Q32 Bio has been sold short.Short Interest Ratio / Days to CoverQ32 Bio has a short interest ratio ("days to cover") of 2.6, which is generally considered an acceptable ratio of short interest to trading volume.Change versus previous monthShort interest in Q32 Bio has recently decreased by 21.19%, indicating that investor sentiment is improving significantly. News and Social Media0.0 / 5News SentimentN/A Search InterestOnly 2 people have searched for QTTB on MarketBeat in the last 30 days. This is a decrease of 0% compared to the previous 30 days. Company Ownership1.7 / 5Insider TradingN/A Insider Buying vs. Insider SellingIn the past three months, Q32 Bio insiders have not sold or bought any company stock.Percentage Held by Insiders40.00% of the stock of Q32 Bio is held by insiders. A high percentage of insider ownership can be a sign of company health.Percentage Held by InstitutionsOnly 31.32% of the stock of Q32 Bio is held by institutions.Read more about Q32 Bio's insider trading history. Receive QTTB Stock News and Ratings via Email Sign-up to receive the latest news and ratings for Q32 Bio and its competitors with MarketBeat's FREE daily newsletter. Email Address QTTB Stock News HeadlinesQ32 Bio Reports First Quarter 2025 Financial Results and Provides Corporate UpdateMay 8, 2025 | prnewswire.comQ32 Bio Announces FDA Fast Track Designation Granted to Bempikibart (ADX-914) for the Treatment of Alopecia AreataApril 30, 2025 | prnewswire.comTrump’s treachery I think Trump’s Treasury Secretary is destroying the stock market on purpose. And no one on Wall Street seems to understand why. Like an addict who needs desperate help, Trump’s Treasury pick, Scott Bessent, is putting America through a “detox period” — and I think it’s going to be absolutely brutal for our economy. Why’s he doing this?May 22, 2025 | Porter & Company (Ad)Leerink Partners Sticks to Its Hold Rating for Q32 Bio (QTTB)April 18, 2025 | markets.businessinsider.comQ32 Bio Doses First Patients in Both Part A Open-Label Extension and Part B of SIGNAL-AA Phase 2a Trial Evaluating Bempikibart in Alopecia AreataApril 16, 2025 | prnewswire.comAnalysts Offer Insights on Healthcare Companies: Roche Holding AG (OtherRHHVF) and Q32 Bio (QTTB)March 12, 2025 | markets.businessinsider.comQ32 Bio price target lowered to $15 from $16 at Wells FargoMarch 12, 2025 | markets.businessinsider.comQ32 Bio Reports Promising Trial Results and FinancialsMarch 12, 2025 | tipranks.comSee More Headlines QTTB Stock Analysis - Frequently Asked Questions How have QTTB shares performed this year? Q32 Bio's stock was trading at $3.44 at the start of the year. Since then, QTTB shares have decreased by 51.7% and is now trading at $1.66. View the best growth stocks for 2025 here. How were Q32 Bio's earnings last quarter? Q32 Bio Inc. (NASDAQ:QTTB) announced its earnings results on Thursday, May, 8th. The company reported ($0.90) EPS for the quarter, beating analysts' consensus estimates of ($1.23) by $0.33. Who are Q32 Bio's major shareholders? Q32 Bio's top institutional investors include Monaco Asset Management SAM (4.14%), Nuveen LLC (0.46%), Goldman Sachs Group Inc. (0.36%) and AQR Capital Management LLC (0.34%). View institutional ownership trends. How do I buy shares of Q32 Bio? Shares of QTTB stock can be purchased through any online brokerage account. Popular online brokerages with access to the U.S. stock market include Charles Schwab, E*TRADE, Fidelity, and Vanguard Brokerage Services. What other stocks do shareholders of Q32 Bio own? Based on aggregate information from My MarketBeat watchlists, some other companies that Q32 Bio investors own include NVIDIA (NVDA), Advanced Micro Devices (AMD), Tesla (TSLA), JPMorgan Chase & Co. (JPM), Meta Platforms (META), Netflix (NFLX) and Alphabet (GOOG). Company Calendar Last Earnings5/08/2025Today5/21/2025Fiscal Year End12/31/2025Get Stock AlertsIndustry, Sector and Symbol Stock ExchangeNASDAQ SectorMedical Industry Pharmaceutical preparations Sub-IndustryPharmaceutical Products Current SymbolNASDAQ:QTTB Previous SymbolNASDAQ:QTTB CIK1661998 Webwww.homologymedicines.com Phone781-301-7277FaxN/AEmployees39Year FoundedN/APrice Target and Rating Average Stock Price Target$24.71 High Stock Price Target$100.00 Low Stock Price Target$3.00 Potential Upside/Downside+1,388.8%Consensus RatingHold Rating Score (0-4)2.25 Research Coverage8 Analysts Profitability EPS (Most Recent Fiscal Year)($4.94) Trailing P/E RatioN/A Forward P/E RatioN/A P/E GrowthN/ANet Income$-112,960,000.00 Net MarginsN/A Pretax MarginN/A Return on Equity-146.18% Return on Assets-54.49% Debt Debt-to-Equity Ratio0.61 Current Ratio6.53 Quick Ratio6.53 Sales & Book Value Annual Sales$-6,651,000.00 Price / Sales-3.04 Cash FlowN/A Price / Cash FlowN/A Book Value$22.47 per share Price / Book0.07Miscellaneous Outstanding Shares12,198,000Free Float10,220,000Market Cap$20.25 million OptionableN/A Beta-0.02 10 "Recession Proof" Stocks That Will Thrive in Any MarketWhich stocks are likely to thrive in today's challenging market? Enter your email address and we'll send you MarketBeat's list of ten stocks that will drive in any economic environment.Get This Free Report This page (NASDAQ:QTTB) was last updated on 5/22/2025 by MarketBeat.com Staff From Our PartnersJuly 2025 Rule Change to Impact Retirement InvestorsThere's a massive change from a new rule going into effect this July. And it's one the Big Banks are alread...Premier Gold Co | SponsoredA new financial chapter Porter Stansberry says what happened last week could become the defining legacy of his financial publishing ca...Porter & Company | SponsoredThe Secret Map of America, Declassified…Locked inside a Maryland man’s private safe is a map. But not just any map, mind you… This map shows a “...Banyan Hill Publishing | SponsoredEveryone’s watching Nvidia right now. Here’s why I’m excited.So, unless you’ve been living under a rock, you probably saw the news… Nvidia just signed a $7 BILLION deal...Timothy Sykes | SponsoredWhite House to reset Social Security?Elon Musk's parting DOGE gift looks set to shock America... A single announcement by July 22nd could soon b...Altimetry | SponsoredElon’s backup plan for AIElon knows the future isn’t about smarter AI — it’s about powering it. And this new technology is quietly b...True Market Insiders | SponsoredExclusive Offer: Target 100% Returns NowBrace yourself–this may come as a shock. It turns out that you may not have to wait decades to turn a small...ProsperityPub | SponsoredPrepare now for May 31 eventPrepare now for May 31 event Circle May 31 on your calendar This man grew up in a trailer in New Mexico. To...Stansberry Research | Sponsored Adding Choose a watchlist: Watchlist Adding You have already added five stocks to your watchlist. Upgrade to MarketBeat All Access to add more stocks to your watchlist. Adding Q32 Bio Inc. Please log in to your account or sign up in order to add this asset to your watchlist. Share Q32 Bio With A Colleague Link copied to clipboard. Get 30 Days of MarketBeat All Access for Free Sign up for MarketBeat All Access to gain access to MarketBeat's full suite of research tools. Start Your 30-Day Trial MarketBeat All Access Features Best-in-Class Portfolio Monitoring Get personalized stock ideas. Compare portfolio to indices. Check stock news, ratings, SEC filings, and more. Stock Ideas and Recommendations See daily stock ideas from top analysts. Receive short-term trading ideas from MarketBeat. Identify trending stocks on social media. Advanced Stock Screeners and Research Tools Use our seven stock screeners to find suitable stocks. Stay informed with MarketBeat's real-time news. Export data to Excel for personal analysis. Sign in to your free account to enjoy these benefits In-depth profiles and analysis for 20,000 public companies. Real-time analyst ratings, insider transactions, earnings data, and more. Our daily ratings and market update email newsletter. Sign in to your free account to enjoy all that MarketBeat has to offer. Sign In Create Account Your Email Address: Email Address Required Your Password: Password Required Log In or Sign in with Facebook Sign in with Google Forgot your password? Your Email Address: Please enter your email address. Please enter a valid email address Choose a Password: Please enter your password. Your password must be at least 8 characters long and contain at least 1 number, 1 letter, and 1 special character. Create My Account (Free) or Sign in with Facebook Sign in with Google By creating a free account, you agree to our terms of service. This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.